We’ve officially entered the “ber” months – September, October, November, and December. That means football, tailgates, fall/winter festivities, and holiday cheer.
And that means seasonal beverages, usually made with warming spirits.
A decade ago, few drinkers gave much thought to what mixers went into their gin and tonic or Moscow mule. Spirits commanded the spotlight; mixers stood in the wings like stagehands.
But the company I want to tell you about today has changed that script. By using natural ingredients, elegant packaging, and the aura of connoisseurship, this London-based firm has elevated mixers to costar status.
That repositioning coincided with the rise of the “drink less, but better” ethos. Millennials and Gen Z’ers drink more selectively, favoring higher-quality products with lower alcohol content, or none at all.
The result was a revolution in cocktail culture. Mixers are now mainstage, and this company – Fevertree Drinks PLC (FEVR.L) – has become the brand that successfully delivers them.
On Thursday, the company released its interim earnings report for fiscal year 2025. On the earnings call, CEO Tim Warrillow cited three global trends shaping the brand’s trajectory: premiumization, moderation, and the rise of longer, lighter drinks. Each trend fuels demand for Fever-Tree products – a portfolio that spans tonics, ginger beer, and sodas.
The real headline from the report, however, was the U.S. market. Fever-Tree’s partnership with Molson Coors Beverage Co. (TAP) is no longer a theoretical growth lever; it is an operational reality. The transition into Molson’s 400 distributors is well underway, and while the second half will still be a handover period, early results are strong.
Now, Fever-Tree’s first-half results were not perfect. But analysts minimized cyclical headwinds to cheer the company’s newfound U.S. growth engine. They correctly recognized that the U.S. transformation and margin resilience bode well for future profit growth.
Shares spiked as much as 11% on the results, with RBC, Jefferies, Goodbody, Citi, and JPMorgan all highlighting the U.S. momentum.
Shares have popped nearly 20% since.
This is great news for my subscribers at The Speculator. I recommended the company to readers at my elite-trading service after my new Apogee system signaled a “Buy” alert on it.
Fever-Tree had passed through all of Apogee’s 10X Factors, which means it has the opportunity to reach 1,000% gains.
The Tanners Creek Super Tournament is a notoriously awful bass fishing competition. The season-ending event has become known as a “grinder tournament” for its challenging conditions and small catches.
Today, many professional AI investors likely feel the same way about the stocks they own. But, as Thomas Yeung explains, you have an investing “superpower.” Here’s what it is…
Eric Fry – once named America’s #1 trader – has discovered the hidden pattern behind his 41-plus gains of 10X or more. Nvidia entered this strange pattern before its epic 60,000% rise. Now five new stocks just entered the pattern – triggering what Eric calls their “10X Confirmation Dates.” He reveals them all, for free, in this presentation (starting with an AI stock that Eric calls “Nvidia on Steroids”). Learn more.
As a native Californian and avid Dodgers fan, it may not come as a surprise that Sandy Koufax is my all-time favorite baseball player. But that’s not the only reason I’m mentioning his historic perfect game 60 years later.
My new stock-picking system, Apogee, hunts for a different kind of perfection: potential 1,000% winners. And it’s already found a stock that looks headed toward 1,000% gains… and I already recommended it. Let me explain…
Eric Fry has 40+ stocks in his track record that have gone on to soar more than 1,000%. But most of those companies would never have made the mainstream news. Eric now says for investors to thrive in the second half of 2025, they need to sell ticking time bombs like Tesla, Nvidia and Amazon. Instead, he’s got three under-the-radar stocks with much higher profit potential. Eric gives away the names and tickers of each of them at no charge in his new “Sell This, Buy That” broadcast. Tune in and stream now…
Oracle may be a legendary tech “old-timer,” but thanks to savvy, forward-looking strategic planning, it has become a dynamic AI play. For starters, it provides industry-leading cloud infrastructure solutions.
And it is time to invest in this next big AI breakthrough – alongside some of the wealthiest people in the world. That’s why I’d like to turn your attention to Elon Musk and his AI robot, Optimus. I think it has the potential to profoundly change the world and go down in history as Musk’s greatest achievement. And I’ve found a ‘backdoor’ way to invest in this new Optimus project. Click here to learn how to invest in this game-changer now.
Every once in a while, Wall Street gets a wake-up call that signals the next chapter of a megatrend. Broadcom just rang that bell. It’s $10-billion custom chip deal marks a turning point in AI hardware, signaling that hyperscalers are moving beyond Nvidia’s GPUs toward specialized XPUs.
Fever-Tree’s recent earnings momentum demonstrates the growing strength of its “cultural moat.”
CEO Warrillow spoke repeatedly of “social occasions” – barbecues, sports events, dinner parties – where Fever-Tree has become embedded. Remember, we’ve recently entered the festive “ber” months.
This cultural embedding is what makes the brand resilient. Competitors can imitate packaging, copy flavors, or undercut on price, but they cannot easily dislodge a brand that has become a cultural default.
Now, the path ahead will not be linear. Spirits categories ebb and flow; weather affects European demand, and execution with Molson will be complex.
But the strategic direction and brand potential are clear: Fever-Tree is becoming a structurally stronger, globally diversified, cash-generative brand.
I expect Fever-Tree to flourish over the coming years.
Fever-Tree is my most recent Apogee recommendation, but it is far from the last. In fact, all of my recommendations at The Speculator will now come from this breakthrough trading system – with my final vetting, of course. Apogee and I always work together.
That means each new recommendation has the opportunity to reach 1,000% gains, just like Fever-Tree.